Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting

NEXT STORY
Akoya Biosciences Announces a Groundbreaking Collaboration with PathAI to Combine Spatial Biology with AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers
PREV STORY
Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MIMEDX Announces Second Quarter 2021 Operating and Financial Results

author_avatar
NASDAQ Market News

Hyris Chalk Up Another Success Fighting COVID19, Providing Canadian Researchers and Medical Specialists With a New Test to Detect T-Cell Immune Response to SARS-CoV-2

author_avatar
NASDAQ Market News

Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)

author_avatar
NASDAQ Market News